Based on the best available evidence, COVID-19 does not appear to cause COPD. A large multicenter study comparing COVID-19 patients to matched controls found identical rates of new COPD diagnoses between the two groups, with no statistical difference at all. However, COVID-19 can cause lasting lung damage that feels a lot like COPD, and the distinction matters for how it’s treated.
What the Research Actually Shows
A multicenter retrospective study published in BMC Medicine compared thousands of COVID-19 patients to a matched group of people who never had the virus. The researchers tracked new diagnoses of obstructive airway diseases over time. For COPD specifically, the hazard ratio was 1.00, meaning the COVID group had exactly the same risk of developing COPD as everyone else. That’s about as definitive a “no” as epidemiology can deliver.
The same study did find that COVID-19 raised the risk of new-onset asthma and bronchiectasis (a condition where airways become permanently widened and scarred). So the virus clearly can damage your lungs in lasting ways. It just doesn’t seem to trigger the specific progressive destruction of air sacs and airways that defines COPD.
Why It Can Feel Like COPD
COVID-19 can leave behind lung changes that produce symptoms nearly identical to COPD: persistent shortness of breath, reduced lung capacity, and chronic cough. About 5% to 9% of people recovering from severe COVID pneumonia show obstructive patterns on breathing tests, the same kind of pattern doctors look for when diagnosing COPD. At 12 months after hospitalization for COVID pneumonia, roughly 35% of patients still reported shortness of breath and 30% still had a cough, according to CDC-published data tracking long-term outcomes.
The lung damage behind these symptoms is real but structurally different from COPD. Researchers examining lung tissue from long-term COVID patients found a consistent pattern: a type of stem cell in the airways (basal epithelial cells) overgrows and spreads into the tiny air sacs where oxygen exchange happens. At the same time, the specialized cells that normally line those air sacs disappear almost entirely. The tissue fills with mucus-producing cells and inflammatory immune cells, and collagen builds up, creating scar-like fibrosis. This process, sometimes called “bronchiolization,” essentially replaces delicate gas-exchanging tissue with thicker airway-type tissue. It’s a form of lung remodeling, but it’s not the same as the progressive air sac destruction seen in emphysema or the chronic airway inflammation of traditional COPD.
How Post-COVID Lung Damage Differs From COPD
COPD is a progressive disease, meaning it gets worse over time, especially with continued exposure to irritants like cigarette smoke. Post-COVID lung damage tends to behave differently. In hospitalized COVID patients whose lung function was impaired at discharge, the average forced vital capacity improved by about 7% over the following year. That pattern of gradual recovery, even if incomplete, is not something you see with COPD.
Imaging also tells a different story. CT scans of post-COVID lungs typically show ground-glass opacities (hazy patches), organizing pneumonia patterns, and a web-like scarring called reticulation. In the largest imaging studies, over 80% of post-COVID patients showed ground-glass changes and reticulation. These findings reflect inflammation and fibrosis, not the hyperinflated, destroyed air sacs characteristic of emphysema on a COPD patient’s scan.
Some post-COVID patients also show a breathing test pattern called PRISm (preserved ratio impaired spirometry), where overall lung function is reduced but the ratio between two key measurements stays normal. This pattern, sometimes called “pre-COPD,” affects the small airways and blood vessels while leaving the lung tissue itself relatively intact. It’s been documented in the general population at rates of 5% to 22%, and it appears in post-COVID patients as well, though researchers are still working out what it means for long-term prognosis.
Who Is Most at Risk for Lasting Lung Problems
The severity of your initial COVID infection is the strongest predictor of long-term lung issues. People who were hospitalized, especially those who needed mechanical ventilation, face the highest risk of persistent breathing problems. Severe COVID pneumonia is the common thread linking nearly all cases of lasting obstructive lung patterns after infection.
If you already have COPD or another lung disease, COVID poses a compounding threat. Smokers and people with COPD have higher levels of the receptor the virus uses to enter cells, which means the virus can take hold more aggressively in already-compromised lungs. An extensive smoking history (25 or more pack-years), baseline lung function below 50% of predicted, and coexisting heart disease or tuberculosis all increase the risk of severe COVID and worse recovery.
People with uncontrolled asthma or those already using oral corticosteroids for lung conditions also face higher hospitalization rates. The combination of pre-existing airway disease and severe COVID infection creates the conditions most likely to produce lasting respiratory impairment.
Treatment for Post-COVID Breathing Problems
If you’re dealing with persistent shortness of breath after COVID, the first step is a bronchodilator test. This simple breathing test measures your lung function before and after inhaling a medication that opens the airways. Research on post-COVID patients in pulmonary rehabilitation found that roughly one-third showed meaningful improvement with a bronchodilator, suggesting their airways were abnormally constricted and could respond to inhaler therapy similar to what’s used for asthma or COPD.
That one-third figure is important because it means bronchodilator therapy won’t help everyone. For the remaining two-thirds, the breathing difficulty likely comes from scarring, fibrosis, or other structural changes that don’t respond to airway-opening medications. Pulmonary rehabilitation, which combines supervised exercise with breathing techniques, is the primary approach for these patients.
The key difference from COPD management is the trajectory. COPD treatment aims to slow an inevitable decline. Post-COVID lung rehabilitation is working with tissue that, in many cases, is still healing. The improvement in lung function measurements over the first year after severe COVID suggests that the body does repair some of this damage on its own, though recovery can be slow and is not always complete.